<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2029">
  <stage>Registered</stage>
  <submitdate>27/06/2008</submitdate>
  <approvaldate>27/06/2008</approvaldate>
  <nctid>NCT00707889</nctid>
  <trial_identification>
    <studytitle>Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer</studytitle>
    <scientifictitle>An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2007-007081-38</secondaryid>
    <secondaryid>M10-300</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Colorectal Cancer</healthcondition>
    <healthcondition>Adenocarcinoma of the Colon</healthcondition>
    <healthcondition>Adenocarcinoma of the Rectum</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-869
Treatment: drugs - bevacizumab
Treatment: drugs - oxaliplatin
Treatment: drugs - folinic acid
Treatment: drugs - fluorouracil
Treatment: drugs - ABT-869

Active Comparator: A - Open-label to Bevacizumab plus mFOLFOX6

Active Comparator: B - Open-label to High-dose ABT-869 arm plus mFOLFOX6

Active Comparator: C - Open-label to low-dose ABT-869 arm plus mFOLFOX6


Treatment: drugs: ABT-869
12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle

Treatment: drugs: bevacizumab
10 mg/kg QD, IV on Day 1 of each 14-day cycle

Treatment: drugs: oxaliplatin
85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle

Treatment: drugs: folinic acid
400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle

Treatment: drugs: fluorouracil
400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours

Treatment: drugs: ABT-869
7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>Radiographic evaluation every 2 months, clinial evaluation every 2 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>from randomization until patient death or alive at 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>12-month overall survival rate</outcome>
      <timepoint>from randomization until patient death or alive at 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate</outcome>
      <timepoint>from randomization until patient death or alive at 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subject must be &gt;/= 18 years of age. Subject (male or female) must be diagnosed with
        adenocarcinoma of the colon or rectum. Subject must have metastatic disease or locally
        recurrent disease that is not amenable to surgical resection with curative intent.

        Subject must have received one prior chemotherapy regimen containing irinotecan or a
        fluoropyrimidine for locally recurrent or metastatic colon or rectal cancer.

        Subject has experienced progressive disease during or following the previous anti-tumor
        treatment.

        Subject may have received prior adjuvant treatment for colorectal cancer. Subject has
        measurable disease by RECIST criteria (randomized portion only). Eastern Cooperative
        Oncology Group (ECOG) Performance Score of 0-1. Subject must have adequate bone marrow,
        renal and hepatic function. Subject must have Partial Thromboplastin Time (PTT) &lt; 1.5 x
        Upper Limit of Normal (ULN) and International Normalized Ratio (INR) &lt; 1.5.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subject has received more than one prior therapy in the metastatic setting. Lead-in Cohort
        only: The subject may have received more than one prior therapy in the metastatic setting.

        Subject has received cytotoxic chemotherapy within 21 days prior to Study Day 1.

        Subject has received non-cytotoxic, anti-cancer therapy within 21 days or within a period
        defined by 5 half lives whichever is shorter, prior to Study Day 1.

        Subject has not recovered to less than or equal to Grade 1 clinically significant adverse
        effects/toxicities of the previous therapy.

        Subject has received prior treatment with a tyrosine kinase inhibitor targeting VEGF or
        PDGF.

        Subject has received prior treatment with oxaliplatin in the metastatic setting. Lead-in
        cohort only: Prior treatment with oxaliplatin will be allowed provided that any neuropathy
        as a result of the oxaliplatin treatment has resolved to less than or equal to Grade 1.

        Subject has had major surgery within 28 days of Study Day 1. Subject has had radiotherapy
        within 14 days of Study Day 1. Subject has a history of hypersensitivity to recombinant
        murine monoclonal antibodies, oxaliplatin or other platinum-containing compounds,
        fluorouracil, or folinic acid.

        Subject has a known intolerance to bevacizumab. Subject has untreated brain or meningeal
        metastases. Subject is receiving therapeutic anticoagulation therapy . Subject has a
        history of/or currently exhibits clinically significant cancer related events of bleeding.

        Subject currently exhibits symptomatic or persistent, uncontrolled hypertension.

        Subject has a history of myocardial infarction, stroke, or transient ischemic attack within
        six months of Study Day 1.

        History of another active cancer within the past 5 years except cervical cancer in situ, in
        situ carcinoma of the bladder, squamous cell or basal cell carcinoma of the skin.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>159</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site Reference ID/Investigator# 18581 - Bedford Park</hospital>
    <hospital>Site Reference ID/Investigator# 23443 - Herston</hospital>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>4029 - Herston</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bonheiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Roeselare</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Jau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Barrie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Edmonton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Nachod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Heraklion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington South</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Aveiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Faro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisbon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Baia Mare</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Brasov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Craiova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santander</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie (prior sponsor, Abbott)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Genentech, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on
      disease progression in advanced colorectal cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00707889</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mark D. McKee, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>